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Abstract
Background: 14-3-3η (eta) is a novel serum/plasma protein biomarker involved in the upregulation of inflammatory
and joint damage factors. We analysed the association of 14-3-3η with the development of clinically apparent arthritis
in a cohort of subjects with arthralgia and positivity for at least one serologic marker: rheumatoid factor (RF) or
anti-citrullinated protein antibody (ACPA).
Methods: Measurement of 14-3-3η in plasma collected on entry into the cohort. For this study, 144 subjects
with a minimum of 2.5 (median and maximum 5) years of follow-up were available. The relationship between
presence and levels of 14-3-3η and development of arthritis was investigated.
Results: Arthritis occurred in 43 (30 %) of the 144 subjects after a median of 15 months. 14-3-3η was detectable
up to 5 years before onset of clinical arthritis and was present significantly more often (36 % versus 14 %; relative
risk 2.5, 95 % confidence interval 1.2–5.6; p = 0.02) and at significantly higher levels (median 0.95 versus 0.28 ng/ml;
p = 0.02) in subjects developing arthritis compared with those who did not. 14-3-3η levels/positivity and ACPA, but not
RF, were univariately associated with the development of arthritis while generalized linear model analysis with RF and
ACPA as obligatory factors could not return an incremental benefit with 14-3-3η.
Conclusions: 14-3-3η was detectable prior to the onset of arthritis and was associated with arthritis development in
arthralgia subjects pre-selected for positivity of RF or ACPA. Its power to predict onset of arthritis independent of ACPA
and RF requires a new study in which patients are not pre-selected based on ACPA and/or RF seropositivity.
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Background
The focus on the management of rheumatoid arthritis
(RA) is increasingly towards early detection and treat-
ment. Better prediction of the development of RA will
potentially allow preventive interventions in these at-risk
individuals. Recently, we published a prediction rule for
the development of arthritis in rheumatoid factor (RF)
and/or anti-citrullinated protein antibodies (ACPA) posi-
tive (seropositive) arthralgia patients [1]. Patients could
be divided into high, intermediate or low risk categories
quite accurately with an area under the receiver operator
characteristic (ROC) curve (AUC) of 0.82 at 5 years.
However, this is still inadequate for individual patient
care – assuming the availability of a preventive inter-
vention; therefore additional biomarkers to improve the
predictive arthritis risk algorithm is required.
Several such potential biomarkers were recently de-
scribed. Examples are anti-carbamylated protein anti-
bodies (anti-Carp) [2], peptidyl arginine deiminase type
4 (anti-PAD-4) [3], and a high interferon gene score [4].
Two of these biomarkers were discovered within the
same patient group as we will describe here [2, 4]. Such
biomarkers may help to improve prediction, but also
offer new insights into the course of events leading to
clinical arthritis.
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Serum 14-3-3η (eta) is a novel protein biomarker
showing potential in predicting radiographic deterior-
ation in early and advanced RA [5, 6]. 14-3-3 proteins
belong to a family of seven isoforms known to bind to
and regulate the biologic activity of various intracellular
proteins [7]. Overexpression of 14-3-3 proteins is asso-
ciated with worse outcomes in various diseases, such as
cancers, neurodegenerative diseases and Creutzfeldt-
Jakob's disease. The 14-3-3η isoform is expressed at
higher levels in patients with arthritis compared with
healthy individuals, which is thought to be related to
14-3-3η's direct ability to induce factors linked to in-
flammation and radiographic damage [8]. 14-3-3η has
been shown to induce inflammatory factors such as
interleukin (IL)-1 and -6, and is linked to the process of
joint damage as it also induces factors such as receptor
activator of nuclear factor-kB ligand (RANKL) and matrix
metalloproteinase (MMP) 1.
In this study, we analysed the association of baseline
14-3-3η with the development of clinically apparent
arthritis in a cohort of subjects with arthralgia who were
pre-selected based on being positive for at least one sero-




From the Reade seropositive arthralgia cohort, the first
144 participants (with ≥30 months of follow-up or devel-
opment of arthritis, included between 2004 and 2008)
were used. This cohort was set up to determine clinical
and serological risk factors for development of arthritis,
and comprises subjects at risk of arthritis, as defined
by arthralgia (no history and no presence of clinically
diagnosed arthritis at the time of their first physical
examination and no erosions on X-rays of hands and
feet) and positivity for at least one serologic marker:
ACPA or RF [9].
Study procedures
At baseline, all participants had clinical and demographic
data collected (including visual analogue scale pain, morn-
ing stiffness, total of painful and swollen joints) and pro-
vided a plasma sample through standard phlebotomy
procedures. Enrolment was based on being positive for
ACPA and/or RF. Plasma was stored at −20 °C until
blinded batch analyses were performed. Following baseline
assessments, all participants were re-assessed at regular
12-month intervals over 5 years with emphasis on the
development of clinical arthritis. An extra visit could be
scheduled in case of arthritis development. Arthritis was
defined based on the presence of at least one swollen joint
on physical examination of 44 joints by a trained medical
doctor (WB or LAS), who was aware of the status of
ACPA and RF in the patient. In case of (uncertain) arth-
ritis according to the first observer, the final judgment
on presence or absence of arthritis was determined by a
senior rheumatologist, who was unaware of the serosta-
tus in the patient (DS). The study was approved by the
Ethics Committee of Slotervaart Hospital and Reade,
Amsterdam, The Netherlands, and written informed
consent was obtained from all study participants.
Detection of biochemical markers
Baseline plasma was assessed for 14-3-3η levels using
the quantitative 14-3-3η enzyme-linked immunosorbent
assay (ELISA, Augurex Life Sciences Corp, Vancouver,
Canada). Positivity for 14-3-3η was defined as ≥0.19 ng/ml
based on the manufacturer's recommended cut-off, and at
2 times and 4 times this cut-off. The development, valid-
ation and calibration of the assay are detailed in a recent
publication [6]. ACPA was measured by an anti-CCP2
ELISA (Axis Shield, Dundee, UK) and immunoglobulin M
rheumatoid factor (IgM-RF) by an in-house ELISA as
described previously [10]. The cut-off level for ACPA posi-
tivity was set at ≥5 arbitrary units/ml (AU/ml), according
to the manufacturer's instructions. The cut-off level for
IgM-RF positivity was set at ≥30 international units/ml
(IU/ml).
Statistical methods
The primary outcome chosen was arthritis, not rheuma-
toid arthritis to prevent circularity, as ACPA and RF are
present in the 2010 American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
RA criteria and 14-3-3η is not. Continuous, normally
distributed data were presented as mean (standard de-
viation) and two-tailed t tests were used to establish
whether significant differences existed between groups.
Non-normally distributed data were presented as median
(interquartile range) and analysed by Mann-Whitney U
tests. Fisher's exact test was used to identify if positivity
for any of the serologic variables investigated (ACPA, RF,
and 14-3-3η) was significantly associated with arthritis
development over 5 years. Spearman’s rank correlation
coefficients expressed the relationship between 14-3-3η
and the other serological markers ACPA and RF. Cox-
proportional hazards survival analysis tested whether
14-3-3η can predict time to arthritis development.
Generalized linear models (GLM) assessed whether
14-3-3η was independently associated with the develop-
ment of arthritis within 5 years. We used GLM with
binomial outcome and log-link function, rather than
standard logistic regression, because of the opportunity
to describe relative risks (RR) instead of odds ratios, as
this is a more proper association measure for describing
results from prospective cohort studies. Since enrolment
in the study implied that a subject was either ACPA or
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RF positive (or both) and no data was obtained in a group
negative on both ACPA and RF, we jointly corrected for
ACPA and RF status using a categorical variable distin-
guishing the three groups: (1) only RF positive, (2) only
ACPA positive, (3) both RF and ACPA positive. Thereafter
we created a variable containing 14-3-3η at different cut-
off points (as mentioned above). In the GLM we first put
in the categorical variable, after which we added 14-3-3η.
The generated p values for 14-3-3η can then be inter-
preted as follows; if significance is found then the 14-3-3η
test adds predictive value to the ACPA and RF test in the
case one or both of these tests are positive. Note that this
significance will imply that the additive value is the same
for all three categories. To test whether predictive per-
formance of 14-3-3η depends on the outcome of the
ACPA and RF test, we also performed interaction analysis
(by adding the interaction between the categorical variable
and 14-3-3η in multivariable analyses). This interaction
analysis will reveal whether 14-3-3η has more predictive
capacity in one of the three groups. All analyses were




Forty-three out of a total of 144 subjects (30 %) devel-
oped arthritis after a median of 15 months (Table 1).
The median follow-up of subjects not developing arth-
ritis was 60 months (minimum 30 months). Ninety-five
percent of the subjects developing arthritis fulfilled the
2010 ACR/EULAR classification criteria for RA [11]. Of
those, 28 % fulfilled the criteria regardless of their ACPA
and RF serostatus. Five subjects had erosions on their
hands or feet X-rays at the time of arthritis diagnosis
(out of 36 subjects with X-rays performed). Compared
with the subjects not developing arthritis, those that did
had significantly more morning stiffness and pain, higher
ACPA levels and positivity, and higher 14-3-3η levels
and positivity at baseline. Importantly, RF, erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)
were not significantly different between the two groups.
At baseline 29 % of subjects used non-steroidal anti-
inflammatory drugs (NSAIDs) and no patients received
hydroxychloroquine. During the course of the study,
42 % used NSAIDs at one or more time points, and 5 %








Time until end of follow-up (censoring or arthritis; months) 60 (1–60) 15 (0–60) 60 (30–60) <0.01
Age (years)* 55 (11) 54 (11) 56 (12) NS
Males (%) 23 28 21 NS
Disease activity
Tender joint count 53 0 (0–5) 0 (0–2) 0 (0–5) NS
Visual analogue scale pain 29 (0–100) 35 (0–100) 26 (0–98) NS
Use of NSAIDs (%) 29 35 26 NS
ESR (mm/hour) 11 (0–34) 11 (0–34) 11 (1–31) NS
CRP (mg/l) 2 (0–47) 2 (0–47) 3 (0–27) NS
Fulfilment of 2010 ACR/EULAR classification criteria for RA (%) NA 95 0 NA
14-3-3η results
Level (ng/ml) 0.35 (0.03–20) 0.95 (0.12–20) 0.28 (0.03–20) <0.01
≥0.19 ng/ml (%) 71 86 64 <0.01
≥0.40 ng/ml (%) 45 58 40 0.04
≥0.80 ng/ml (%) 33 51 24 <0.01
RF results
Level (IU/ml) 38 (1–1192) 31 (1–383) 40 (1–1192) NS
Positivity (%) 63 61 63 NS
ACPA results
Level (AU/ml) 108 (0–9860) 455 (0–8710) 59 (0–9860) <0.01
Positivity (%) 65 95 53 <0.01
Abbreviations: NS not significant, NSAIDs non-steroidal anti-inflammatory drugs, ESR erythrocyte sedimentation rate, CRP C-reactive protein, NA not applicable,
RA rheumatoid arthritis, RF rheumatoid factor, IU/ml international units/ml, ACPA anti-citrullinated protein antibodies, AU/ml arbitrary units/ml, (p value ≥0.05)
*Mean (SD), all other continuous variables mentioned as median (min-max)
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received hydroxychloroquine (of these patients, five did
not develop arthritis whilst two did). Notably, 31 sub-
jects (22 %) received 1–2 dexamethasone injections after
baseline in a double-blind trial (which did not delay or
prevent arthritis development) [9].
Serological biomarkers 14-3-3η, ACPA and RF
As represented in Table 1, median 14-3-3η expression
levels at baseline were significantly higher in the 43
subjects who developed arthritis in comparison with 101
subjects that did not develop arthritis (median 0.95 vs
0.28, p <0.01). Table 1 together with Fig. 1 demonstrate
that the prevalence of 14-3-3η positivity at baseline was
significantly greater in those patients that developed
arthritis in comparison with those that did not at the
different cut points (86 % vs 64 %, p <0.01; 58 % vs
40 %, p = 0.04; 51 % vs 24 %, p <0.01 for cut-offs
0.19, 0.4 and 0.8 respectively). Also, the distribution
of positivity for ACPA, RF and 14-3-3η and the different
combinations between those that developed arthritis and
Fig. 1 Distribution of positivity for ACPA, RF and 14-3-3η in a cohort of arthralgia patients. Top panel: different combinations of positive markers
between the subjects developing arthritis versus those who do not; expressed as proportions. Bottom panel: percentage of positivity of each
marker in the subjects developing arthritis versus those who do not (*Means a statistically significant difference with a p value <0.01).
Abbreviations: 1433 14-3-3η protein (cut-off ≥0.19 ng/ml), ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
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those who did not is outlined in Fig. 1. It shows that
subjects developing arthritis were either in the subgroup
of ACPA/14-3-3η positives (30 %) or ACPA/RF/14-3-3η
positives (52 %). Spearman's rank sum revealed that levels
of 14-3-3η were moderately correlated with those of RF
and ACPA (0.30 and 0.31, respectively; p <0.01). Perform-
ance characteristics of 14-3-3η were as follows for the
0.19 cut-off point (manufacturer's recommended cut-off):
sensitivity 36 %, specificity 86 %, positive predictive value
86 % and negative predictive value 36 %. Univariate GLM
analysis indicated that baseline 14-3-3η positivity signifi-
cantly predicted arthritis development delivering RRs of
2.5 (p = 0.02), 1.7 (p = 0.04) and 2.2 (p <0.01) at the cut-off
points ≥0.19, ≥0.40 and ≥0.80 ng/ml, respectively (Table 2,
upper part). GLM evaluating 14-3-3η levels further re-
vealed 14-3-3η's association with the arthritis outcome,
with an RR of 1.04 (p = 0.01). As previously reported from
this cohort, ACPA positivity had a strong association with
arthritis development (RR 10.9, p <0.01, measured univari-
ately), but RF positivity did not. In multivariable GLM
(Table 2, lower part) 14-3-3η levels and positivity at all
cutoff points were corrected for the autoantibody status of
ACPA and/or RF. Since we used a categorical variable for
ACPA and/or RF presence, the generated p values for
14-3-3η can be interpreted as predictive capacity of
14-3-3η in the case one or both of these ACPA/RF
tests are positive. In this situation, neither 14-3-3η
levels nor positivity at any cut-off point added value
to the prediction of arthritis development. In the inter-
action analyses the added value of a positive 14-3-3η test
did not differ between subjects that were only RF positive,
only ACPA positive or those who were positive for both
tests. No significant relation between either 14-3-3η posi-
tivity or levels and time of arthritis onset could be found
in the Cox proportional hazards model (data not shown).
Subgroup analysis of subjects with certain combinations
of biomarkers, for example 14-3-3η positivity in ACPA
negative versus positive subjects, was not feasible due to
small subgroups.
Discussion
This study presents data that 14-3-3η is present in the
pre-clinical phase of arthritis development, since there
was a greater proportion of positivity of this marker at
study entry together with higher expression in a pre-
selected cohort of ACPA- and/or RF-positive arthralgia
subjects who developed arthritis, compared with those
who did not. This may be related to 14-3-3η’s ability
to induce various inflammatory and joint degradative
factors [6, 8].
Since 14-3-3η is an inflammatory mediator, the mech-
anism through which it is related to the development of
arthritis may be different from that of autoantibodies
such as ACPA and RF, whose levels tend to remain static
or unchanged over the course of one’s disease. In this
regard, a possible link of 14-3-3η with non-specific mea-
sures of inflammation, such as ESR and CRP, might be
revealing. However, measurements of ESR and CRP at
baseline were related neither to development of arthritis
nor to 14-3-3η positivity in this cohort (data not shown).
Another difference with autoantibodies might be the
dynamic nature of serum 14-3-3η, which was supported
by a study in first-degree relatives of indigenous North
Americans with RA [12]. This study population was
not suitable for serial measurements since half of the
patients developed arthritis shortly after inclusion and
therefore missed a secondary measurement of 14-3-3η.
In this study, although 14-3-3η was associated with
the development of arthritis, baseline 14-3-3η levels and
positivity at three cut-off points did not add predictive
value to the combination of ACPA and RF. This is most
likely influenced by both the pre-selection method for
this cohort, the ascertainment of arthritis, as well as the
dynamic nature of 14-3-3η. In particular, the blinded
confirmatory rheumatologist reviewed only those sus-
pected of developing arthritis, and not all 144 subjects.
Since the unblinded physician was making the initial
assessment of arthritis development, if a bias did exist
Table 2 Univariate and multivariable association of 14-3-3η,
ACPA and RF with arthritis development
Univariate logistic regression
Variable RR (95 % CI) p value
14-3-3η
Cut-off ≥0.19 2.5 (1.2–5.6) 0.02
Cut-off ≥0.40 1.7 (1.0–2.8) 0.04
Cut-off ≥0.80 2.2 (1.3–3.5) <0.01
Levels 1.04 (1.01–1.07) 0.01
Multivariable logistic regression
Variable RR (95 % CI) p value
Categorical variable:
RF Reference
ACPA 7.9 (1.9–32.4) <0.01
RF and ACPA 15.0 (3.8–59.7) <0.01
Adding 14-3-3η to the above categorical variable
14-3-3η ≥0.19 1.6 (0.7–3.5)* 0.25
14-3-3η ≥0.40 1.2 (0.7–1.8) 0.52
14-3-3η ≥0.80 1.3 (0.8–2.1) 0.36
14-3-3η levels 1.01 (0.98–1.04)** 0.50
Abbreviations: ACPA anti-citrullinated protein antibodies, RF rheumatoid factor,
RR relative risk, CI confidence interval
*Interpretation of the relative risk, example: subjects that are 14-3-3η positive
at the 0.19 cut-off point have a 1.6 times higher risk of developing arthritis,
given the knowledge that these subjects must be either RF or ACPA positive
**For continuous variables the relative risk conveys the higher risk of
developing arthritis per ascending unit of the independent variable, in this
case 14-3-3η
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from their knowledge of ACPA and RF status, the blinded
confirmatory physician would have reviewed a predomin-
ance of, say, ACPA-positive subjects and therefore identi-
fied more arthritis among those who were ACPA positive.
For clinical practice it would be very useful if 14-3-3η
positivity could enhance the prediction of (rheumatoid)
arthritis when combined with ACPA and RF. One such
study that would enable such an analysis comes from a
cohort of subjects based on clinically suspect arthralgia
at risk for RA rather than on the basis of positive ser-
ology results. In addition to this, a prospective cohort
recruited based on the presence of either of the three
markers ACPA, RF or 14-3-3η may avoid any under-
estimation of the predictive capacity of 14-3-3η [13].
Another suggestion would be to use a design which
includes serial measurements of 14-3-3η. The OMER-
ACT working group has recommended this design in
guidelines to study soluble biomarkers, aimed at clin-
ical validation of their predictive capacity, particularly
for prognostic end points [14]. The major limitation
of baseline assessment alone has been repeatedly em-
phasized, particularly for responsive biomarkers such
as 14-3-3η, which could vary considerably over the course
of disease, and also with therapeutic intervention. This is
highlighted in a recent publication describing clinical
validation of IL-6 as a predictor of an event where longitu-
dinal, but not baseline assessment alone, was predictive of
structural damage in RA [15]. The publication is about
progression of radiographic damage, but it applies to other
end points as well. However, a single assessment does
conform with the clinical situation where a decision is
often made to follow the patient or not.
Another limitation of this study was that the primary
outcome could not be rheumatoid arthritis, as ACPA
and RF are part of the 2010 ACR/EULAR classification
criteria and 14-3-3η is not. We explored alternative
outcomes such as subjects fulfilling the ACR/EULAR
criteria regardless of serostatus and the development of
erosions, but not enough subjects were positive for
either to allow meaningful analysis.
Conclusions
In conclusion, we have shown that 14-3-3η is often
present in arthralgia subjects positive for ACPA and/or RF
prior to the development of arthritis, and was associated
with the development of arthritis. In this cohort of sub-
jects pre-selected for ACPA and/or RF positivity the added
predictive value of 14-3-3η, both levels and different cut-
off points, could not be established. Further studies are
warranted to assess the combined utility of these three
markers in predicting the development of arthritis.
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